Teva Wins UK Patent Challenge Against AZ’s Symbicort

Drug Industry Daily
A A
Teva is clear to market its version of AstraZeneca’s chronic obstructive pulmonary disorder drug Symbicort in the United Kingdom, after the High Court there struck down an AZ indication patent on grounds of obviousness.

To View This Article:

Login

Subscribe To Drug Industry Daily